Insider Trading Alert - ANAC, N And PRAA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 24, 2014, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $820.00 to $144,690,560.42.

Highlighted Stocks Traded by Insiders:

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Parker Geoffrey M. who is Senior Vice President and CFO at Anacor Pharmaceuticals bought 5,000 shares at $20.11 on March 24, 2014. Following this transaction, the Senior Vice President and CFO owned 163,410 shares meaning that the stake was reduced by 3.16% with the 5,000-share transaction.

Maples Kirk R who is SVP, Program Management at Anacor Pharmaceuticals sold 3,000 shares at $22.39 on March 24, 2014. Following this transaction, the SVP, Program Management owned 4,620 shares meaning that the stake was reduced by 39.37% with the 3,000-share transaction.

The shares most recently traded at $20.02, down $2.37, or 11.83% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 86,000
  • 24-Week # shares sold: 89,000

The average volume for Anacor Pharmaceuticals has been 483,800 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $887.4 million and is part of the health care sector and drugs industry. Shares are up 19.07% year-to-date as of the close of trading on Monday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company has a P/E ratio of 10.7. Currently there are 2 analysts that rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings rates Anacor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Anacor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NetSuite (N) - FREE Research Report

Solomon Douglas P. who is SVP, General Counsel & Sec. at NetSuite sold 450 shares at $104.52 on March 24, 2014. Following this transaction, the SVP, General Counsel & Sec. owned 28,607 shares meaning that the stake was reduced by 1.55% with the 450-share transaction.

The shares most recently traded at $96.71, down $7.81, or 8.08% since the insider transaction. Historical insider transactions for NetSuite go as follows:

  • 4-Week # shares sold: 30,101
  • 12-Week # shares sold: 51,801
  • 24-Week # shares sold: 169,621

The average volume for NetSuite has been 469,900 shares per day over the past 30 days. NetSuite has a market cap of $7.6 billion and is part of the technology sector and computer software & services industry. Shares are down 6.77% year-to-date as of the close of trading on Monday.

NetSuite Inc. provides cloud-based financials/enterprise resource planning (ERP) and omnichannel commerce software suites in the United States and internationally. Currently there are 8 analysts that rate NetSuite a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on N - FREE

TheStreet Quant Ratings rates NetSuite as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full NetSuite Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Portfolio Recovery Associates (PRAA) - FREE Research Report

Petit Michael J who is President -Bankruptcy Services at Portfolio Recovery Associates sold 5,000 shares at $58.28 on March 24, 2014. Following this transaction, the President -Bankruptcy Services owned 54,223 shares meaning that the stake was reduced by 8.44% with the 5,000-share transaction.

The shares most recently traded at $57.70, down $0.58, or 1.01% since the insider transaction. Historical insider transactions for Portfolio Recovery Associates go as follows:

  • 4-Week # shares sold: 47,825
  • 12-Week # shares sold: 100,096
  • 24-Week # shares sold: 129,132

The average volume for Portfolio Recovery Associates has been 576,800 shares per day over the past 30 days. Portfolio Recovery Associates has a market cap of $2.9 billion and is part of the services sector and diversified services industry. Shares are up 8.69% year-to-date as of the close of trading on Monday.

Portfolio Recovery Associates, Inc., a financial and business service company, is engaged in the purchase, collection, and management of portfolios of defaulted consumer receivables in the United States and the United Kingdom. The company has a P/E ratio of 16.8. Currently there are 4 analysts that rate Portfolio Recovery Associates a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRAA - FREE

TheStreet Quant Ratings rates Portfolio Recovery Associates as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Portfolio Recovery Associates Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices